

Oligonucleotide synthesis market: The therapeutic segment is expected to witness significant growth during 2021 to 2030

The global oligonucleotide synthesis market is projected to reach \$ 26.099 billion by 2030 registering a CAGR of 17.10% from 2021 to 2030.

PORTLAND, OREGON, UNITED STATES, April 21, 2023 /EINPresswire.com/ -- The global oligonucleotide synthesis market was valued at \$51.97 billion in 2020 and is projected to reach \$ 26.099 billion by 2030 registering a CAGR of 17.1% from 2021 to 2030.

•CAGR: 17.1%

• Current Market Size: USD 197.5 Million

Forecast Growing Region: APAC
Largest Market: North America
Projection Time: 2021- 2030

• Base Year: 2021



000000 000000 000000: https://www.alliedmarketresearch.com/request-sample/8721

The oligonucleotide synthesis market is experiencing steady growth due to increasing demand for synthetic DNA and RNA molecules in various applications such as research, diagnostics, and therapeutics. Oligonucleotide synthesis refers to the process of chemically synthesizing short strands of nucleic acids, typically consisting of 20-100 nucleotides. These synthesized oligonucleotides find application in various fields such as gene editing, gene therapy, synthetic biology, and diagnostics.

The oligonucleotide synthesis market is segmented into product type, application, end-user, and geography. Based on product type, the market is divided into synthesized oligonucleotides, reagents, equipment, and services. The synthesized oligonucleotides segment holds the largest market share, owing to the increasing demand for synthetic DNA and RNA molecules for various

applications. The reagents and equipment segments are also expected to witness significant growth during the forecast period, due to the increasing adoption of automated synthesizers and high-throughput screening systems.

Based on application, the market is segmented into research, diagnostics, and therapeutics.

The research segment holds the largest market share, owing to the increasing demand for synthetic oligonucleotides in research applications such as gene editing, gene expression analysis, and synthetic biology. The diagnostics segment is expected to witness significant growth during the forecast period, owing to the increasing adoption of oligonucleotide-based diagnostic tests for infectious diseases, cancer, and genetic disorders. The therapeutics segment is also expected to witness significant growth, owing to the increasing demand for oligonucleotide-based drugs for the treatment of various diseases such as cancer, rare genetic disorders, and viral infections.

Based on end-user, the market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations. The pharmaceutical and biotechnology companies segment holds the largest market share, owing to the increasing demand for synthetic oligonucleotides for drug discovery and development. The academic and research institutes segment is expected to witness significant growth during the forecast period, owing to the increasing adoption of synthetic oligonucleotides in research applications. The contract research organizations segment is also expected to witness significant growth, owing to the increasing demand for outsourcing of oligonucleotide synthesis services.

Geographically, the oligonucleotide synthesis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds the largest market share, owing to the presence of a large number of pharmaceutical and biotechnology companies, academic and research institutes, and increasing adoption of synthetic oligonucleotides in research and diagnostic applications. Europe is the second-largest market, owing to the increasing investment in research and development activities and the presence of a large number of academic and research institutes. The Asia Pacific region is expected to witness significant growth during the forecast period, owing to the increasing investment in research and development activities and the increasing adoption of oligonucleotide-based diagnostic tests.

00 0000000 0000000 000000 000000 - https://www.alliedmarketresearch.com/purchase-enquiry/8721

- ALNYLAM PHARMACEUTICALS, INC.,
- · BIOGEN LIMITED,

- CINVEN, DANAHER CORPORATION,
- EUROFINS SCIENTIFIC,
- IONIS PHARMACEUTICALS, INC.,
- KANEKA CORPORATION,
- MERCK KGAA,
- SAREPTA THERAPEUTICS, INC.,
- THERMO FISHER SCIENTIFIC, INC.

 $\ \, 00000\ \, 000000000\ \, 0000000\ \, -$

00000 00000 00000- https://www.alliedmarketresearch.com/cough-syrup-market-A10312

- https://www.alliedmarketresearch.com/sterilization-services-market-A07513

David Correa Allied Analytics LLP +1 800-792-5285 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/629244119

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.